Atrinsic (NASDAQ:PTIX) Stock Price Up 10.9% – Should You Buy?

Atrinsic Inc. (NASDAQ:PTIX)’s stock price traded up 10.9% during trading on Tuesday . The company traded as high as $0.50 and last traded at $0.50. 2,974 shares were traded during mid-day trading, a decline of 96% from the average session volume of 77,387 shares. The stock had previously closed at $0.4507.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Atrinsic in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Atrinsic has an average rating of “Sell”.

Atrinsic Stock Performance

The firm has a market cap of $811,880.80, a price-to-earnings ratio of -0.05 and a beta of 1.03. The business has a fifty day moving average of $0.60 and a two-hundred day moving average of $2.00.

Atrinsic Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.